Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179868 · ClinicalTrials.gov registry record
C-Reactive Protein as a Predictor of Stem Cell Transplant Complications
A clinical trial of Cancer and Leukemia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Completed
- Registry status
- 70
- Enrollment target
- 1
- Study location
NCT00179868: Completed study of Cancer and Leukemia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
NCT00179868 is a study of Cancer and Leukemia that has completed, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 70 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00179868, a study of Cancer and Leukemia, has completed, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- COMPLETED
- Registry status
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if C-Reactive Protein levels are predictive for complications post transplant.
Conditions Studied
Interventions
- BEHAVIORAL C-Reactive Protein levels
Study Locations (1)
Illinois
- Children's Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2003-01 |
| Est. Completion | 2008-02 |
What the finished NCT00179868 record still lists
NCT00179868 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which C-Reactive Protein levels is the first listed.
NCT00179868 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00179868 about?
NCT00179868 is a clinical study titled "C-Reactive Protein as a Predictor of Stem Cell Transplant Complications". The purpose of this study is to determine if C-Reactive Protein levels are predictive for complications post transplant.
What is the current status of trial NCT00179868?
This trial is currently completed. The enrollment target is 70 participants. The study started on 2003-01. Estimated completion is 2008-02.
What conditions does trial NCT00179868 study?
This clinical trial studies the following conditions: Cancer, Leukemia, Stem Cell Transplantation.
What interventions are being tested in trial NCT00179868?
The interventions under investigation include: C-Reactive Protein levels (BEHAVIORAL).
Who is sponsoring clinical trial NCT00179868?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00179868 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00179868's enrollment target sits among peer trials
70 373rd of 615 higher than 236 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia